Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor, FLT3).

CAS：120685-11-2
中文别名：
英文别名：4\'-N-benzoyl staurosprine;PKC 412,[9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3\',2\',1\'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide;Midostaurin;Benzoylstaurosporine;Cgp 41 251;4\'-N-benzoylstaurosporine;
分子式：C35H30N4O4
分子量：570.637
精确质量：570.227
Psa：77.73
Logp：6.2356

UNII：ID912S5VON

密度：1.46g/cm3
折射率：1.76
储存条件：Store at 2-8ºC

危险品标志：T